Dr. John P P. Fruehauf, MD

Dr. Fruehauf practices at UCI Health - Orange in Orange, California, part of UC Irvine.

Dr. Fruehauf's NPI, 1588744635, was assigned on October 16, 2006. Dr. Fruehauf graduated from Rush Medical College in 1985. Dr. Fruehauf holds California license 000000G58826.

Dr. Fruehauf's primary practice is UCI Health - Orange, at 101 City Drive South, Orange, CA 92868 in Orange County. The practice phone is (714) 456-7890.

Dr. Fruehauf's primary practice is UCI Health - Orange in Orange, California, part of UC Irvine. The medical group on file is UCI Health Physicians. Dmand AI also links Dr. Fruehauf to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Fruehauf practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Fruehauf's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Fruehauf is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Fruehauf's licenses on file in 11 states: California, Texas, Hawaii, Illinois, Kentucky, Maryland, Mississippi, Arizona, Georgia, Washington and Nevada.

CMS data shows 217 Medicare services from Dr. Fruehauf across 2 procedure codes in 2024, all of them office visits, for 79 Medicare patients. Medicare paid $27,614 for them. Every service was in an office.

CMS counts 79 Medicare patients who saw Dr. Fruehauf in 2024. The largest group is 75 to 84, with 39 patients. 68% of them have high blood pressure, and 65% have high cholesterol. Their average risk score is 2.62, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Fruehauf's median patient age at 75, with 28% women.

In 2024, Dr. Fruehauf wrote 223 Medicare Part D claims for 41 patients. 65% of them were for generic drugs. CMS names the drug for 94 of them, across 4 drugs with 11 or more claims each, at $509,020 in total drug cost. In 2023, CMS named 259 claims across 13 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Fruehauf for performance year 2024, reported through an alternative payment model (APM). Dr. Fruehauf accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Fruehauf as offering telehealth.

Dmand AI links 61 papers to Dr. Fruehauf, published from 2006 to 2024. 2009 was the busiest year, with 2. The most frequent topics are Melanoma, Tumor Cells, Cultured and Breast Neoplasms. Dr. Fruehauf has published most often in Gynecol Oncol. Dr. Fruehauf's most frequent co-authors are Robert A. Burger, MD, Bradley J. Monk, MD and Rita Sanghvi S. Mehta, MD.

Dmand AI links Dr. Fruehauf to 11 clinical trials, 7 of them phase 2 studies. Conditions studied include Melanoma, Nevi and Melanomas and Prostatic Neoplasms. University of California, Irvine sponsors the most, 5.

CMS Open Payments shows 231 general payments to Dr. Fruehauf from 8 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 71% of the total. Novartis Pharmaceuticals Corporation paid the most, $108,259.

Dmand AI lists 4 awards for Dr. Fruehauf, most recently Top Doctors:LA Area in 2013.

Dr. Fruehauf graduated from Rush Medical College in 1985. Dr. Fruehauf is a member of ACP and ASCO.

Dr. Fruehauf is in network with 9 carriers, including Elevance, Blue Cross Blue Shield of Michigan and United Healthcare. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.